Eli Lilly (NYSE:LLY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before market open. The ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

According to Eli Lilly: Zepbound is available for people without ... Zepbound for people whose doctors have prescribed it off-label. Off-label means that a doctor prescribes a medication for ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... heart failure in 2021 and secured an expanded label in a hard-to-treat population the next year.

Over the past six months, Eli Lilly (NYSE ... the active ingredient in Mounjaro and Zepbound, is still undergoing many clinical trials and should earn key label expansions. Last year, the medicine ...